Biochemist, Ph.D. in Biomedical Sciences, professor in Chemistry, Biochemistry, Toxicology and Pharmacology at the Faculty of Medicine, University of Chile. Principal Investigator and head of the Laboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF). Chairman of the Latin American Society of Pharmacogenomics and personalized Medicine. Co-founder of the first Center of Bioequivalence (IFT) in Chile placed at the University of Chile. Expert on Pharmaceutical Patents for the Ministry of Economy of Chile (INAPI). Dr. Quiñones’ team has made key contributions in the area of pharmacogenetic/pharmacokinetic, epidemiological and clinical aspects of cancer and other diseases. Particularly, his laboratory has studied polymorphisms of several pharmagenes related with susceptibility, pharmacological treatment and prognosis of lung, prostate, gastric, breast, oral, larynx and testicular cancer.

Luis Abel Quinones research area is focus on molecular pharmacology and toxicology and is based in his expertise in drug metabolism. Currently his research group tightly collaborates with several Latin American researchers, Dr. José Agúndez (Spain), Dr. Constanza Camargo (NIH-USA), and at least five clinical centers in Chile [National Institute of Cancer (INC), Arturo Lopez Perez Foundation (FALP), University of Chile Clinical Hospital (HCUCH), Barros Lucco Hospital and San Juan de Dios Hospital]. Dr. Quiñones has authored more than 80 peer–reviewed papers in international journals, 1 book, 5 book chapters and 4 pharmaceutical patents.